Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Acetaminophen toxicity induces mitochondrial complex I inhibition in human liver tissue

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pharmacokinetics of Ferric bepectate - a new intravenous iron drug for treating iron deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Short-course vs long-course antibiotic treatment for community-acquired pneumonia: A literature review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects with Hepatic Steatosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Glucagon-like peptide-1 (GLP-1)-based therapies, GLP-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4Is) are widely used for the treatment of type 2 diabetes. Increasing evidence suggests that they may provide neuroprotection. The aim of this MiniReview was to systematically evaluate the proposed mechanism of action for GLP-1-based therapies in ischaemic brain damage in animals. We performed a literature search using MEDLINE, EMBASE and The Cochrane Library. GLP-1-based therapies administered before, during or after experimental stroke in diabetic and non-diabetic animals were evaluated. We reviewed 27 studies comprised of 20 involving GLP-1RAs and seven involving DPP-4Is. Both GLP-1RAs and DPP-4Is affected the acute inflammatory response secondary to ischaemia by reducing inflammation, endothelial leakage and excitotoxicity. Both treatments also reduced oxidative stress and apoptosis. GLP-1RAs significantly reduced infarct volume when administered acutely, but not later after stroke. The reported effects of DPP-4Is on infarct volume were inconsistent. GLP-1-RAs reliably improved functional outcome, but the effects on cerebral blood flow were inconclusive. These neuroprotective effects were often attributed to activation of the GLP-1 receptor, but non-GLP-1R-mediated effects have also been suggested. Both GLP-1RAs and DPP-4Is significantly affected inflammation, oxidative stress and apoptosis in animal stroke models; however, data from clinical trials only report therapeutic efficacy for GLP-1RAs. Thus, GLP-1RA administration is the most promising treatment to pursue for patients at risk of stroke or immediately after stroke. Future studies should address acute and prophylactic treatments in stroke patients with and without diabetes.

OriginalsprogEngelsk
TidsskriftBasic & clinical pharmacology & toxicology
Vol/bind122
Udgave nummer6
Sider (fra-til)559-569
Antal sider11
ISSN1742-7843
DOI
StatusUdgivet - jun. 2018

ID: 56565500